9781108658867 (ebook) 9781108470995 (hardback) 9781108456937 (paperback)
Transparency is a concept that is becoming increasingly lauded as a solution to a host of problems in the American health care system. Transparency initiatives show great promise, including empowering patients and other stakeholders to make more efficient decisions, improve resource allocation, and better regulate the health care industry. Nevertheless, transparency is not a cure-all for the problems facing the modern health care system. The authors of this volume present a nuanced view of transparency, exploring ways in which transparency has succeeded and ways in which transparency initiatives have room for improvement. Working at the intersection of law, medicine, ethics, and business, the book goes beyond the buzzwords to the heart of transparency's transformative potential, while interrogating its obstacles and downsides. It should be read by anyone looking for a better understanding of transparency in the health care context.
Title from publisher's bibliographic system (viewed on 19 Jun 2019).
Formatted Contents Note
Machine generated contents note: Introduction Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch and Barbara J. Evans; Part I. Transparency in Health and Health Care: Thematic Issues: Introduction Abigail R. Moncrieff; 1. Smashing into windows: 'the limits of consumer sovereignty in health care' Barry R. Furrow; 2. The interplay of privacy and transparency in health care: the HIPAA privacy rule as a case study Barbara J. Evans; 3. Transparency tradeoffs: priority-setting, scarcity, and health fairness Govind Persad; 4. Slightly hazy: transparency and the costs of too much information Oliver J. Kim; Part II. Transparency and Informed Consent: Introduction Luke Gelinas; 5. Transparency versus informed consent: the patient/consumer paradigms Craig J. Konnoth; 6. Transparency and financial conflicts: the uncertain case for sunshine Richard S. Saver; 7. Making religion transparent: the substance, process, and efficacy of disclosing religious restrictions on care Elizabeth Sepper; Part III. Transparency and Economics: Health Care Costs and Billing: Introduction Kristin M. Madison; 8. Transparency on prescription drug research expenditures: a lever for restraining pricing? Ameet Sarpatwari, Jerry Avorn and Aaron S. Kesselheim; 9. Is pharmaceutical price transparency an effective means to reduce high prices and wide variations? Marc A. Rodwin; 10. Price transparency: a contracts solution Wendy Netter Epstein; 11. Solving surprise medical bills Mark A. Hall; Part IV. Transparency and Innovation: Introduction Holly Fernandez Lynch; 12. Increasing the transparency of FDA review to enhance the innovation process Rachel E. Sachs and Thomas J. Hwang; 13. Transparency and clinical trial data sharing: legal and policy issues Barbara E. Bierer, Mark Barnes and Rebecca Li; 14. The European Medicines Agency's approach to transparency Stefano Marino and Spyridon Drosos; Part V. Transparency and Outcomes: Promoting Health and Safety: Introduction Gregory Curfman; 15. The role of transparency in promoting healthy behaviors: pros, cons, and perils of information sharing to foster personal responsibility in health care Anthony W. Orlando and Arnold J. Rosoff; 16. The role of transparency in patient safety improvement Michelle M. Mello, David M. Studdert, Brahmajee K. Nallamothu and Allen Kachalia; 17. Personal health records as a tool for transparency in health care Sharona Hoffman; 18. Nontransparency in electronic health record systems Jim Hawkins, Barbara J. Evans and Harlan M. Krumholz; 19. Transparency challenges in reproductive health care Dov Fox; Part VI. Challenges in Promoting and Measuring Transparency in Health Care: Introduction I. Glenn Cohen; 20. ERISA as a barrier for state health care transparency efforts Erin C. Fuse Brown and Jaime S. King; 21. Transparency and data sharing in clinical research and Big Pharma Jennifer E. Miller; 22. Promoting IRB transparency: about what, to whom, why, and how? Holly Fernandez Lynch; 23. Using disclosure to regulate PBMs: the dark side of transparency David A. Hyman and William E. Kovacic.